Sarepta shares surge after FDA lifts pause on muscular dystrophy treatment

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares surged 25% after the FDA lifted a voluntary pause on shipments of its gene therapy ELEVIDYS for ambulatory Duchenne muscular dystrophy (DMD) patients. The regulator's decision followed a determination that a recent patient death was unrelated to the therapy, clearing the way for resumed US shipments. Jefferies analysts anticipate only a modest impact on Q3 sales, projecting reaccelerated growth that could see ELEVIDYS reach $500 million annually by 2027, bolstering investor confidence, while Sarepta aims for broader approval in non-ambulatory DMD, forecasting its total DMD franchise could generate $1.4 billion annually by 2027.

Analysis

Sarepta Therapeutics (SRPT) experienced a significant 25% share price increase following the U.S. Food and Drug Administration's recommendation to lift a voluntary pause on its gene therapy, ELEVIDYS, for ambulatory Duchenne muscular dystrophy (DMD) patients. This regulatory green light was prompted by the FDA's determination that a recent patient death was unrelated to the therapy, a crucial validation of the drug's safety profile which has been demonstrated in over 760 treated ambulatory patients without any linked fatalities. The operational impact is expected to be minimal, as the week-long pause is projected by Jefferies analysts to have only a 'modest' effect on third-quarter sales, with growth likely reaccelerating in the latter half of the year. This development shores up the commercial outlook for ELEVIDYS, with analysts projecting a potential sales floor of $500 million annually by 2027. However, a key risk remains as the pause for the non-ambulatory DMD patient cohort is still in effect. Sarepta's ability to resolve safety concerns in this population, potentially through the use of sirolimus, and resume the ENVISION confirmatory study will be critical to unlocking the full potential of its DMD franchise, which the company internally forecasts could reach $1.4 billion in annual revenue by 2027.

Key Decisions for Investors

• The FDA's clearance for ELEVIDYS in ambulatory patients substantially de-risks the near-term revenue stream and validates a core component of the company's DMD franchise, supporting the stock's recent positive momentum.
• Investors should now focus on the key remaining risk and catalyst: Sarepta's progress in resuming the ENVISION study for non-ambulatory DMD, as success in this larger patient population is critical to achieving the forecasted $1.4 billion franchise potential.
• Financial models can be updated to reflect the minimal expected impact on Q3 sales and Jefferies' projection of a $500 million annual sales floor for ELEVIDYS, providing a tangible baseline for near-term valuation.